BackgroundBreast neoplasms are the second most common type of cancer worldwide, and radiation therapy is a key component of their treatment. Acute skin reactions are one of the most common side effects of radiation therapy, and prevention of this adverse event has been investigated in several studies. However, a clinically applicable, preventative treatment remains unavailable. It has been demonstrated that application of a low-power laser can promote tissue repair. Therefore, the aim of this trial is to evaluate the effectiveness of an indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm in preventing radiodermatitis in women undergoing adjuvant radiotherapy for breast cancer.Methods/DesignThis is a two-arm, randomized controlled trial. A total of 52 patients undergoing radiotherapy for breast cancer (stages I to III) will be enrolled. Patients will be randomly assigned to an intervention group to receive laser therapy (n = 26) or a control group to receive a placebo (n = 26). The laser or placebo will be applied five days a week, immediately before each radiotherapy session. Skin reactions will then be graded weekly by a nurse, a radiotherapist, and an oncologist (all of whom will be blinded) using the Common Toxicity Criteria (CTC) developed by the National Cancer Institute and the Acute Radiation Morbidity Scoring Criteria developed by the Radiation Therapy Oncology Group. Patients will also answer a modified visual analogue scale for pain (a self-evaluation questionnaire). Primary and secondary outcomes will be the prevention of radiodermatitis and pain secondary to radiodermatitis, respectively.DiscussionThe ideal tool for preventing radiodermatitis is an agent that mediates DNA repair or promotes cell proliferation. Application of a low-power laser has been shown to promote tissue repair by reducing inflammation and inducing collagen synthesis. Moreover, this treatment approach has not been associated with adverse events and is cost-effective. Thus, the results of this ongoing trial may establish whether use of a low-power laser represents an ideal treatment option for the prevention of radiodermatitis.Trial registrationClinicalTrials.gov identifier: NCT02003599. Registered on 2 December 2013.Electronic supplementary materialThe online version of this article (doi:10.1186/1745-6215-15-330) contains supplementary material, which is available to authorized users.
Objetivo. Comparar a terapia de contensão induzida (TCI) e esta associada à eletroestimulação funcional (FES) no membro superior parético de indivíduos com acidente vascular cerebral (AVC). Método. Amostra de 12 indivíduos divididos em 2 grupos (n=6): grupo I – TCI e grupo II – TCI associada à FES. Os indivíduos deveriam apresentar histórico de AVC, hemiparesia, no mínimo 10° de extensão do punho e estado cognitivo preservado. Foram avaliados antes e ao final das sessões e após 2 meses do término dessas. Para avaliação foram utilizados: Mini-Exame do Estado Mental, Escala de Avaliação Motora de Fugl- Meyer, goniometria e escala manual de força muscular. Realizou-se 10 sessões com duração de 3 horas por um período de 2 semanas, sendo que o grupo II realizou 10 minutos a mais para aplicação da FES. Resultados. Obteve-se uma melhora significante na função do membro parético no grupo I; na goniometria da extensão do punho em ambos os grupos e na força muscular dos músculos flexores do punho no grupo II. Comparando-se os grupos, não houve diferença estatística entre eles. Conclusão. Não houve diferença entre as técnicas utilizadas, devendo-se ressaltar que independente do tipo da técnica utilizada o indivíduo se beneficiará com o tratamento fisioterápico.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.